Mo Qatanani Sells 1,936 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Mo Qatanani sold 1,936 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $8.58, for a total value of $16,610.88. Following the sale, the insider now owns 142,768 shares of the company’s stock, valued at $1,224,949.44. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Scholar Rock Price Performance

Scholar Rock stock opened at $9.39 on Friday. The company’s 50 day moving average is $8.93 and its two-hundred day moving average is $11.26. The firm has a market cap of $751.48 million, a PE ratio of -4.49 and a beta of 0.82. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 0.36. Scholar Rock Holding Co. has a 52-week low of $6.03 and a 52-week high of $21.17.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.01. During the same period in the previous year, the firm posted ($0.47) earnings per share. On average, research analysts expect that Scholar Rock Holding Co. will post -2.39 EPS for the current fiscal year.

Analysts Set New Price Targets

SRRK has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Scholar Rock in a research report on Tuesday, June 25th. BMO Capital Markets upped their price objective on shares of Scholar Rock from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, Wedbush reissued an “outperform” rating and issued a $23.00 price target on shares of Scholar Rock in a research note on Thursday, August 8th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $26.43.

Institutional Trading of Scholar Rock

Institutional investors have recently bought and sold shares of the business. Amalgamated Bank boosted its holdings in shares of Scholar Rock by 15.5% in the 4th quarter. Amalgamated Bank now owns 4,869 shares of the company’s stock valued at $92,000 after buying an additional 652 shares in the last quarter. American International Group Inc. raised its stake in shares of Scholar Rock by 3.0% during the 1st quarter. American International Group Inc. now owns 28,407 shares of the company’s stock worth $505,000 after buying an additional 834 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Scholar Rock by 1.0% during the 1st quarter. Jennison Associates LLC now owns 138,458 shares of the company’s stock worth $2,459,000 after purchasing an additional 1,409 shares in the last quarter. Rice Hall James & Associates LLC raised its stake in Scholar Rock by 3.6% in the 2nd quarter. Rice Hall James & Associates LLC now owns 46,000 shares of the company’s stock valued at $383,000 after purchasing an additional 1,594 shares during the last quarter. Finally, ProShare Advisors LLC grew its holdings in Scholar Rock by 11.7% in the 1st quarter. ProShare Advisors LLC now owns 15,412 shares of the company’s stock valued at $274,000 after buying an additional 1,620 shares during the period. 91.08% of the stock is owned by hedge funds and other institutional investors.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.